{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:15:16Z","timestamp":1778681716884,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s12185-026-04164-8","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:11:41Z","timestamp":1770106301000},"page":"767-775","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bronchiolitis obliterans complicating follicular lymphoma: a case series and clinical insights"],"prefix":"10.1007","volume":"123","author":[{"given":"Takashi","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaharu","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Katsube","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoko","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroto","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayaka","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Tanoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yo","family":"Sakayori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iku","family":"Kamitani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keitaro","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Numata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Araya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"issue":"2","key":"4164_CR1","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1200\/jco.18.00400","volume":"37","author":"C Sarkozy","year":"2019","unstructured":"Sarkozy C, Maurer MJ, Link BK, Ghesquieres H, Nicolas E, Thompson CA, et al. Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. J Clin Oncol. 2019;37(2):144\u201352. https:\/\/doi.org\/10.1200\/jco.18.00400.","journal-title":"J Clin Oncol"},{"issue":"25","key":"4164_CR2","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1056\/nejm199012203232503","volume":"323","author":"GJ Anhalt","year":"1990","unstructured":"Anhalt GJ, Kim SC, Stanley JR, Korman NJ, Jabs DA, Kory M, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med. 1990;323(25):1729\u201335. https:\/\/doi.org\/10.1056\/nejm199012203232503.","journal-title":"N Engl J Med"},{"key":"4164_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18122532","author":"G Paolino","year":"2017","unstructured":"Paolino G, Didona D, Magliulo G, Iannella G, Didona B, Mercuri SR, et al. Paraneoplastic pemphigus: insight into the autoimmune pathogenesis, clinical features and therapy. Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms18122532.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4164_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s12026-018-8986-7","volume":"66","author":"K Kridin","year":"2018","unstructured":"Kridin K. Pemphigus group: overview, epidemiology, mortality, and comorbidities. Immunol Res. 2018;66(2):255\u201370. https:\/\/doi.org\/10.1007\/s12026-018-8986-7.","journal-title":"Immunol Res"},{"issue":"2","key":"4164_CR5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1378\/chest.117.2.603","volume":"117","author":"M Takahashi","year":"2000","unstructured":"Takahashi M, Shimatsu Y, Kazama T, Kimura K, Otsuka T, Hashimoto T. Paraneoplastic pemphigus associated with bronchiolitis obliterans. Chest. 2000;117(2):603\u20137. https:\/\/doi.org\/10.1378\/chest.117.2.603.","journal-title":"Chest"},{"issue":"1","key":"4164_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1159\/000357109","volume":"132","author":"K Morikawa","year":"2014","unstructured":"Morikawa K, Tsuji T, Yamasaki H, Egashira S, Kaguchi A, Kido M, et al. Paraneoplastic pemphigus occurs most commonly in indolent B cell lymphoma. Acta Haematol. 2014;132(1):73\u20134. https:\/\/doi.org\/10.1159\/000357109.","journal-title":"Acta Haematol"},{"issue":"7","key":"4164_CR7","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/1346-8138.12521","volume":"41","author":"M Kanaoka","year":"2014","unstructured":"Kanaoka M, Matsukura S, Ishikawa H, Matsuura M, Ishii N, Hashimoto T, et al. Paraneoplastic pemphigus associated with fatal bronchiolitis obliterans and appearance of anti-BP180 antibodies in the late stage of the disease. J Dermatol. 2014;41(7):628\u201330. https:\/\/doi.org\/10.1111\/1346-8138.12521.","journal-title":"J Dermatol"},{"issue":"2","key":"4164_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3960\/jslrt.55.83","volume":"55","author":"T Hirano","year":"2015","unstructured":"Hirano T, Higuchi Y, Yuki H, Hirata S, Nosaka K, Ishii N, et al. Rituximab monotherapy and rituximab-containing chemotherapy were effective for paraneoplastic pemphigus accompanying follicular lymphoma, but not for subsequent bronchiolitis obliterans. J Clin Exp Hematopathol. 2015;55(2):83\u20138. https:\/\/doi.org\/10.3960\/jslrt.55.83.","journal-title":"J Clin Exp Hematopathol"},{"issue":"6","key":"4164_CR9","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1007\/s12185-017-2305-2","volume":"106","author":"S Lee","year":"2017","unstructured":"Lee S, Yamauchi T, Ishii N, Hashimoto T, Kinoshita K, Imamura S, et al. Achievement of the longest survival of paraneoplastic pemphigus with bronchiolitis obliterans associated with follicular lymphoma using R-CHOP chemotherapy. Int J Hematol. 2017;106(6):852\u20139. https:\/\/doi.org\/10.1007\/s12185-017-2305-2.","journal-title":"Int J Hematol"},{"issue":"1","key":"4164_CR10","first-page":"7","volume":"60","author":"K Watanabe","year":"2019","unstructured":"Watanabe K, Yoshifuji K, Saito T, Yamashita T, Nogami A, Sakashita C, et al. Follicular lymphoma accompanied by paraneoplastic pemphigus and bronchiolitis obliterans: a case report. [Rinsho ketsueki] Japanese j clin hematol. 2019;60(1):7\u201311.","journal-title":"[Rinsho ketsueki] Japanese j clin hematol"},{"issue":"7","key":"4164_CR11","first-page":"1915","volume":"13","author":"S Wu","year":"2020","unstructured":"Wu S, Gao D, Zhang Y, Yang P, Wang Y, Wang N, et al. Follicular lymphoma with paraneoplastic pemphigus as the first symptom: a case report and review of the literature. Int J Clin Exp Pathol. 2020;13(7):1915\u201323.","journal-title":"Int J Clin Exp Pathol"},{"issue":"4","key":"4164_CR12","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1684\/ejd.2020.3812","volume":"30","author":"M Yoshikawa","year":"2020","unstructured":"Yoshikawa M, Takeichi T, Taki T, Hayakawa F, Ishii N, Hashimoto T, et al. A case of pemphigus with anti-desmoglein 3 and anti-desmocollin 2 and 3 autoantibodies, associated with follicular lymphoma and bronchiolitis obliterans. Eur J Dermatol. 2020;30(4):424\u20135. https:\/\/doi.org\/10.1684\/ejd.2020.3812.","journal-title":"Eur J Dermatol"},{"issue":"3","key":"4164_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.5021\/ad.2021.33.3.271","volume":"33","author":"M Kim","year":"2021","unstructured":"Kim M, Lee JY, Kim SC, Na JI. A case of paraneoplastic pemphigus as a preceding manifestation of underlying follicular lymphoma treated with R-CHOP. Ann Dermatol. 2021;33(3):271\u20134. https:\/\/doi.org\/10.5021\/ad.2021.33.3.271.","journal-title":"Ann Dermatol"},{"issue":"2","key":"4164_CR14","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00277-021-04499-8","volume":"101","author":"T Kishi","year":"2022","unstructured":"Kishi T, Nakata J, Yamada T, Nakatsuka S, Matsuura A, Shibano M. Fatal progression of bronchiolitis obliterans in spite of complete remission of follicular lymphoma and paraneoplastic pemphigus. Ann Hematol. 2022;101(2):453\u20135. https:\/\/doi.org\/10.1007\/s00277-021-04499-8.","journal-title":"Ann Hematol"},{"issue":"2","key":"4164_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2021.100813","volume":"46","author":"K Kuriyama","year":"2022","unstructured":"Kuriyama K, Kitamura Y, Tsuji T, Nishikawa R, Nagata H, Ohshiro M, et al. Successful treatment of paraneoplastic pemphigus and bronchiolitis obliterans associated with follicular lymphoma with obinutuzumab and bendamustine. Curr Probl Cancer. 2022;46(2):100813. https:\/\/doi.org\/10.1016\/j.currproblcancer.2021.100813.","journal-title":"Curr Probl Cancer"},{"issue":"8","key":"4164_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.70274","volume":"39","author":"K Amirali","year":"2025","unstructured":"Amirali K, Zahra K, Maryam B, Amir Ali H. Treatment options for bronchiolitis obliterans secondary to hematopoietic cell transplantation in children: a systematic review. Clin Transplant. 2025;39(8):e70274.","journal-title":"Clin Transplant"},{"issue":"11","key":"4164_CR17","doi-asserted-by":"publisher","DOI":"10.12890\/2019_001266","volume":"6","author":"K Nozaki","year":"2019","unstructured":"Nozaki K, Ezoe S, Hamaguchi M, Tsutsumi K, Kusakabe S, Morikawa Y, et al. Unexpected complication of R-CHOP chemotherapy: rapidly progressive bronchiolitis obliterans syndrome. Eur J Case Rep Intern Med. 2019;6(11):001266. https:\/\/doi.org\/10.12890\/2019_001266.","journal-title":"Eur J Case Rep Intern Med"},{"issue":"3","key":"4164_CR18","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1016\/j.chest.2017.01.023","volume":"151","author":"T Nishihara","year":"2017","unstructured":"Nishihara T, Nakano H, Nogami H, Katahira K, Ishimatsu A, Hashimoto N, et al. A 63\u00a0year-old woman with progressive dyspnea after remission of lymphoma. Chest. 2017;151(3):e57\u201362. https:\/\/doi.org\/10.1016\/j.chest.2017.01.023.","journal-title":"Chest"},{"issue":"2","key":"4164_CR19","first-page":"281","volume":"3","author":"T Nishihara","year":"2014","unstructured":"Nishihara T, Katahira K, Nogami H, Hashimoto N, Iwanaga T. A case of bronchiolitis obliterans diagnosed after chemotherapy for malignant lymphoma. Ann Japanese Respir Soci. 2014;3(2):281\u20136.","journal-title":"Ann Japanese Respir Soci"},{"issue":"5","key":"4164_CR20","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/j.1445-5994.2012.02778.x","volume":"42","author":"T Shen","year":"2012","unstructured":"Shen T, Braude S. Obliterative bronchiolitis after rituximab administration: a new manifestation of rituximab-associated pulmonary toxicity. Intern Med J. 2012;42(5):597\u20139.","journal-title":"Intern Med J"},{"key":"4164_CR21","volume":"2012","author":"BE Ahmet","year":"2012","unstructured":"Ahmet BE, Nancy F, Hamed AD. Rituximab-induced bronchiolitis obliterans organizing pneumonia. Case Rep Med. 2012;2012:680431.","journal-title":"Case Rep Med"},{"issue":"2","key":"4164_CR22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/JID.2015.408","volume":"136","author":"T Atsunari","year":"2016","unstructured":"Atsunari T, Sanae N, Kwesi T, Yohei N, Tamihiro K, Yoshito T, et al. Epiplakin is a paraneoplastic pemphigus autoantigen and related to bronchiolitis obliterans in japanese patients. J Invest Dermatol. 2016;136(2):399\u2013408.","journal-title":"J Invest Dermatol"},{"issue":"10","key":"4164_CR23","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.autrev.2018.04.008","volume":"17","author":"KT Amber","year":"2018","unstructured":"Amber KT, Valdebran M, Grando SA. Paraneoplastic autoimmune multiorgan syndrome (PAMS): beyond the single phenotype of paraneoplastic pemphigus. Autoimmun Rev. 2018;17(10):1002\u201310. https:\/\/doi.org\/10.1016\/j.autrev.2018.04.008.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"4164_CR24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4049\/jimmunol.1203536","volume":"191","author":"T Hata","year":"2013","unstructured":"Hata T, Nishimoto S, Nagao K, Takahashi H, Yoshida K, Ohyama M, et al. Ectopic expression of epidermal antigens renders the lung a target organ in paraneoplastic pemphigus. J Immunol. 2013;191(1):83\u201390. https:\/\/doi.org\/10.4049\/jimmunol.1203536.","journal-title":"J Immunol"},{"key":"4164_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106432","volume":"97","author":"IG Solman","year":"2020","unstructured":"Solman IG, Blum LK, Hoh HY, Kipps TJ, Burger JA, Barrientos JC, et al. Ibrutinib restores immune cell numbers and function in first-line and relapsed\/refractory chronic lymphocytic leukemia. Leuk Res. 2020;97:106432. https:\/\/doi.org\/10.1016\/j.leukres.2020.106432.","journal-title":"Leuk Res"},{"key":"4164_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1132535","volume":"10","author":"C Chen","year":"2023","unstructured":"Chen C, Xu Y, Yu J, Qian S, Xie Y. A first case of successful using of ibrutinib in treating paraneoplastic pemphigus related bronchiolitis obliterans concurrent with CLL. Front Med. 2023;10:1132535. https:\/\/doi.org\/10.3389\/fmed.2023.1132535.","journal-title":"Front Med"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04164-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04164-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04164-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:30:02Z","timestamp":1778679002000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04164-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4164"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04164-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K. Suzuki received personal fees from Janssen Pharmaceutical K.K., Sanofi, Pfizer, Glaxo Smith Kline K.K., Bristol Meyers Squibb, Takeda Pharmaceutical Company, and Ono Pharmaceutical Company, outside the submitted work. T. Gunji received personal fees from Janssen Pharmaceutical K.K., outside the submitted work. S. Yano received personal fees from Daiichi-Sankyo and AstraZeneca and grants from Otsuka Pharmaceutical Company, Lilly Pharma, and Fuji Pharma, outside the submitted work. The other authors declare that they have no conflict of interest. Dr. Kazuhito Suzuki serves as an editor of\n                      International Journal of Hematology\n                      .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}